Journal article
Impact of p16 Status and Anatomical Site in Anti-PD-1 Immunotherapy-Treated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients
Cancers, Vol.13(19), p.4861
09/28/2021
DOI: 10.3390/cancers13194861
PMCID: PMC8508514
PMID: 34638345
Abstract
Simple Summary
Anti-PD-1 immunotherapies are approved for head and neck squamous cell carcinoma in the recurrent/metastatic setting, and utilization of these high-cost biologics is expected to increase as other indications are approved. Due to the high cost and selective response rate of these immunotherapy biologics in HNSCC, it is imperative to better define which patient subsets will realize a clinically meaningful benefit with anti-PD-1 treatment. The impact of anatomical site and p16 status on the efficacy of anti-PD-1 inhibitors remains unresolved. We showed that anatomical site and p16 status are associated with overall survival in anti-PD-1-treated HNSCC patients from a single-institution, real-world cohort.
In head and neck squamous cell carcinoma (HNSCC), anti-PD-1 inhibitors are approved for recurrent/metastatic (R/M) disease and anticipated to expand to other indications. The impact of p16 status and anatomical site on overall survival (OS) in immunotherapy-treated HNSCC patients remains unresolved. We performed a retrospective analysis of R/M HNSCC patients receiving anti-PD-1 immunotherapy at our academic medical center with an extensive community satellite network. Fifty-three R/M HNSCC patients were treated with anti-PD-1 immunotherapy and had a median OS of 6 months. Anatomical site was associated with distinct OS; oropharynx and larynx patients have superior OS compared to oral cavity patients. Analysis of the OPSCC subset showed p16+ status as a favorable, independent prognostic biomarker (HR 7.67 (1.23-47.8); p = 0.029). Further studies to assess the link between anatomical site, p16 status, and anti-PD-1 treatment outcomes in large cohorts of R/M HNSCC patients managed in real-world clinical practices and clinical trials should be prioritized.
Details
- Title: Subtitle
- Impact of p16 Status and Anatomical Site in Anti-PD-1 Immunotherapy-Treated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients
- Creators
- Kate Clancy - University Hospitals of ClevelandChelsea S. Hamill - University Hospitals of ClevelandW. Quinn O'Neill - University Hospitals Seidman Cancer CenterBrandon Vu - University Hospitals Seidman Cancer CenterJason Thuener - University Hospitals Seidman Cancer CenterShanying Gui - University Hospitals Seidman Cancer CenterShawn Li - University Hospitals of ClevelandNicole Fowler - University Hospitals Seidman Cancer CenterRod Rezaee - University Hospitals of ClevelandPierre Lavertu - University Hospitals of ClevelandJay Wasman - University Hospitals of ClevelandMonaliben Patel - University Hospitals of ClevelandHira Shaikh - University of CincinnatiEric Vick - University of CincinnatiAnant Madabhushi - Case Western Reserve UniversityTrisha M. Wise-Draper - University of CincinnatiKyunghee Burkitt - University Hospitals of ClevelandTheodoros N. Teknos - University Hospitals Seidman Cancer CenterQuintin Pan - University Hospitals Seidman Cancer Center
- Resource Type
- Journal article
- Publication Details
- Cancers, Vol.13(19), p.4861
- Publisher
- Mdpi
- DOI
- 10.3390/cancers13194861
- PMID
- 34638345
- PMCID
- PMC8508514
- ISSN
- 2072-6694
- eISSN
- 2072-6694
- Number of pages
- 9
- Grant note
- National Institute of Craniofacial and Dental Research; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR) University Hospitals Seidman Cancer Center R01DE023555; R01CA193590 / National Cancer Institute of the National Institutes of Health; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)
- Language
- English
- Date published
- 09/28/2021
- Academic Unit
- Internal Medicine
- Record Identifier
- 9984695836702771
Metrics
4 Record Views